A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

Inclusion Criteria:

* Signed informed consent form (ICF)
* ≥ 18 years of age at the time of signing the ICF
* Eastern Cooperative Oncology Group performance status of 0 to 2
* Adequate bone marrow reserve
* Adequate coagulation function, liver/pancreas function, and renal function
* No clinically significant abnormalities in the levels of serum electrolytes
* Life expectancy \>12 weeks
* Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 3 months after the last dose of study intervention:

  * Refrain from donating sperm, AND either:
  * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent, OR
  * Must agree to use an approved contraception method
* A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

  * Woman of non-childbearing potential (WONCBP)
  * Woman of childbearing potential (WOCBP) and using an effective contraceptive method
* A WOCBP must have a negative highly sensitive pregnancy test within 72 hours of the first dose of study intervention

Inclusion Criteria for Dose Finding Phase Only:

* Have a histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor that has progressed after prior standard therapy, been intolerant to or is ineligible for standard therapy, or has a malignancy for which there is no approved therapy considered standard of care

Inclusion Criteria for Dose Expansion Phase Only:

* Histologically or cytologically confirmed colorectal adenocarcinoma that has progressed on or is intolerant to treatment from fluoropyrimidine, oxaliplatin, and irinotecan. Participants may have received bevacizumab, anti-epidermal growth factor receptor monoclonal antibody, or checkpoint inhibitor as appropriate.
* Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 criteria

Exclusion Criteria:

* Primary central nervous system (CNS) tumor or symptomatic CNS metastases that are neurologically unstable or have required increasing doses of steroids within the 4 weeks prior to study entry to manage CNS symptoms (symptomatic brain metastases that have been adequately treated are not excluded)
* Any clinically significant cardiac disease defined as New York Heart Association class III or IV within the 6 months before Screening
* History of ≥ Grade 3 pancreatitis
* History of intracranial thrombosis or history of recurrent thrombosis (except for catheter-related thrombosis)
* Active (significant or uncontrolled) gastrointestinal bleeding
* Active uncontrolled infection (≥ Grade 2) at the time of enrollment
* HIV-positive, unless:

  * CD4+ count ≥ 300/μL;
  * Undetectable viral load; AND
  * Receiving highly active antiretroviral therapy
* Uncontrolled infection of hepatitis B or hepatitis C or diagnosis of immunodeficiency

  * Participants with Hepatitis B who have controlled infection are permitted. Participants with controlled infections must undergo periodic monitoring of Hepatitis B virus DNA. Participants must remain on antiviral therapy for ≥ 6 months beyond the last dose of study intervention.
* Pregnant (or plan to be pregnant) or lactating woman
* History of any severe or uncontrolled medical condition
* Unresolved toxicity, based on the investigator's assessment of the participant, from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment, except for stable conditions ≤Grade 2 (ie, neuropathy, myalgia, fatigue, alopecia, therapy-related endocrinopathies)
* Prior treatment with JZP341 or any other asparaginase